Gilead Sciences reports fiscal Q1 2026 results: revenue $6.96B, up 4% from a year earlier

Gilead Sciences filed a Form 8-K with the SEC on May 7, 2026, 4:03 PM ET, reporting an event dated May 7, 2026. It covers Item 2.02 (Results of Operations and Financial Condition); Item 9.01 (Financial Statements and Exhibits). The results cover fiscal Q1 2026 (quarter ended Mar 31, 2026); figures below are from the company's XBRL financial data filed with the SEC.

• Revenue: $6.96B (+4.4% from $6.67B a year earlier)
• Operating income: $2.59B (+15.6% from $2.24B a year earlier)
• Net income: $2.02B (+53.7% from $1.31B a year earlier)
• Diluted EPS: $1.61 (+54.8% from $1.04 a year earlier)
• Form 8-K accepted by EDGAR May 7, 2026, 4:03 PM ET
• Accession number 0000882095-26-000022

SEC filing 8-K · accession 0000882095-26-000022 · sec.gov ↗